AmorChem invests in project targeting neurological disorders

AmorChem has made an undisclosed investment in a project focused on regulatory mechanisms involved in the innate immune response in neurological disorders. AmorChem, a Canadian life sciences venture capital firm, will through a partnership with Laval University and Québec City's CERVO Brain Research Centre, fund development of a project on the checkpoint control target SRSF3 in the laboratory of Dr Jasna Kriz. The project aims to identify new treatments for central nervous system diseases. AmorChem invested through its $46-million second seed-stage fund, AmorChem II Fund LP, backed by Fondaction, Fonds de solidarité FTQ, Merck and other limited partners.